In Its Own Words: FDA Explains Stance On Antihypertensive Combinations
Executive Summary
The agency explains the policy it uses, which has not been put out in a formal guidance, in a preamble to the questions for the cardio-renal advisory committee’s review of Actavis’ nebivolol/valsartan combo.